Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture

Hepatology Research

Volumn 37, Issue 11, 2007, Pages 941-947

  Liu, Chen ^a,d   Zhu, Haizhen ^a   Subramanian, Mani G ^b   Moore, Paul A ^b   Xu, Yiling ^c   Nelson, David R ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NONE   (United States)

Author keywords

Albinterferon alfa 2b; Gene expression; Hepatitis C virus; Replicon

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA2B INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IFI27; TRANSCRIPTION FACTOR IFI44; TRANSCRIPTION FACTOR OAS1; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 34548610612     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00142.x     Document Type: Article

References (22)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Modi MW, Lamb MW, Shiomi M. Peginterferon alfa-(40 KD): A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C. Adv Exp Med Biol 2003; 519: 59-67.
7. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.
8. Osborn BL, Olsen HS, Nardelli B et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-8.
9. Bain VG, Yoshida EM, Kaita KD et al. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res 2006; 35: 256-62.
10. Balan V, Nelson DR, Sulkowski MS et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006; 11: 35-45.
11. Bain VG, Kaita KD, Yoshida EM et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671-8.
12. Fiscella M, Balan V, Nelson D et al. Favorable pharmacokinetics of albumin interferon alfa-2b in subjects with chronic hepatitis C. Hepatology 2006; 44 (Suppl. 1): 613A (Abstract) 1140.
13. McHutchison J, Zeuzem S, Benhamou Y et al. Interim antiviral and safety data with albumin interferon alfa-2b combined with ribavirin in a phase 2b study conducted in subjects with genotype 1, IFN-naïve, chronic hepatitis C infection. Hepatology 2006; 44 (Suppl. 1): 611A (Abstract) 1141.
14. Nelson D, Rustgi V, Balan V et al. Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: Interim results from A Phase 2 study. Hepatology 2006; 44 (Suppl. 1): 611A (Abstract) 1136.
15. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21.
16. Zhu H, Zhao H, Crawford J, Nelson D, She J, Liu C. Gene expression associated with IFN anti-hepatitis C viral activity in a replicon cell line. Hepatology 2003; 37: 1180-88.
17. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-13.
18. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-4.
19. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-90.
20. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003; 77: 9204-10.
21. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516-23.
22. Zhu H, Nelson DR, Crawford JM, Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J Interferon Cytokine Res 2005; 25: 528-39.